Table 3.
Selected Trials of Allogeneic Stem Cell Transplant for Hodgkin Lymphoma
| Study | No. Patients | Graft | Regimen | NRM/TRM | OS (%) | PFS (%) | Relapse |
|---|---|---|---|---|---|---|---|
| Myeloablative Conditioning | |||||||
| Gajewski et al.33 | 100 | MRD | Various, TBI: 45% | 3-y: 61 | 3-y: 21 | 3-y: 15 | 3-y: 65 |
| Milpied et al.32 | 45 | MRD | Various | 4-y: 48 | 4-y: 25 | 4-y: 15 | 4-y: 61 |
| Akpek et al.49 | 53 | MRD | Various | 10-y: 53 | 10-y: 30 | 10-y: 26 | 10-y: 53 |
| Reduced-Intensity Conditioning | |||||||
| Robinson et al.37 | 285 | MRD, URD | Various | 1-y: 19.5 | 3-y: 29 | 3-y: 25 | 5-y: 59 |
| 3-y: 21.1 | |||||||
| Sarina et al.38 | Donor: 63 vs. no donor: 185 | MRD, URD, Haplo | Various | 14 | 2-y: 66 | 2-y: 39 | NA |
| 5 | 2-y: 42 | 2-y: 14 | |||||
| Peggs et al.41 | (+) Mab: 31 | MRD,URD | Flu/Mel | 2-y: 7 | 4-y: 62 | 2-y: 39 | 3-y: 54 |
| (−) Mab: 36 | Flu/Mel | 2-y: 28 | 4-y: 39 | 2-y: 25 | 3-y: 44 | ||
| Devetten et al.50 | 143 | URD | Various | 2-y: 33 | 2-y: 37 | 2-y: 20 | 2-y: 47 |
| RIC | |||||||
| Anderlini et al.51 | 58 | MRD, URD | Flu/Mel | 2-y: 15 | 2-y: 64 | 2-y: 32 | 2-y: 55 |
| Alvarez et al.52 | 40 | MRD | Flu/Mel | 1-y: 25 | 2-y: 48 | 2-y: 32 | NA |
| Burroughs et al.40 | 90 total | ||||||
| 38 | MRD, URD | Flu/TBI | 1-y: 21 | 2-y: 53 | 2-y: 23 | 2-y: 56 | |
| 24 | Haplo | Flu/TBI | 1-y: 8 | 2-y: 58 | 2-y: 29 | 2-y: 63 | |
| 28 | Flu/TBI/Cy | 1-y: 9 | 2-y: 58 | 2-y: 51 | 2-y: 40 | ||
Abbreviations: Cy, cyclophosphamide; Flu, fludarabine; Haplo, haploidentical donor; Mab, alemtuzumab; Mel, melphalan; MRD, matched related donor; NA, not available; NRM, nonrelapse mortality; OS, overall survival; PFS, progression-free survival; RIC, reduced-intensity conditioning; TBI, total body irradiation; TRM, transplant-related mortality; URD, unrelated donor.